John M. Leonard, President and CEO at Intellia Therapeutics, Inc. (NTLA), sold 176,292 shares at $9.59 ($1.7M) on 2025-12-11, disclosed to the SEC on 2025-12-12.
Scheduled sale ($1.7M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.47 | 32,832 | $311K | 18.6% |
| 2 | $9.47 | 32,832 | $311K | 18.6% |
| 3 | $9.49 | 49,959 | $474K | 28.3% |
| 4 | $9.49 | 49,959 | $474K | 28.3% |
| 5 | $9.59 | 5,355 | $51K | 3.1% |
| 6 | $9.59 | 5,355 |
| $51K |
| 3.1% |
| Total | $9.49 avg | 176,292 | $1.7M | 100% |
| Filing → |
| NTLA | SELL | 2025-01-07 | $653K | — | Filing → |
| NTLA | SELL | 2024-01-05 | $1.1M | — | Filing → |
| NTLA | SELL | 2023-01-06 | $497K | — | Filing → |